Ocugen, Inc. 8-K

What Happened

• On January 15, 2026, Ocugen, Inc. announced positive preliminary 12‑month data from both its Phase 1 and Phase 2 ArMaDa trials evaluating OCU410 (AAV5‑RORA), a modifier gene therapy for geographic atrophy secondary to dry age‑related macular degeneration (GA from dry AMD). The company filed a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) with this Form 8‑K.
• The Form 8‑K includes a standard cautionary note that these are preliminary results and that final data, further analyses, or regulatory review could lead to different conclusions.

Key Details

• Date of filing/announcement: January 15, 2026.
• Trials: Positive preliminary 12‑month data reported from both Phase 1 and Phase 2 ArMaDa trials.
• Therapy: OCU410 (AAV5‑RORA), targeted at geographic atrophy secondary to dry AMD.
• Documents filed: Press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2) attached to the 8‑K.

Why It Matters

• For investors, positive 12‑month clinical data is an important clinical milestone that can affect the perceived value and development prospects of Ocugen’s gene‑therapy pipeline (OCU410).
• The filing does not report financial results, regulatory approvals, or definitive efficacy/safety conclusions—results are described as preliminary and accompanied by forward‑looking statements cautioning that final data or regulatory assessments may differ.
• Investors should view this as a clinical progress update; any investment or valuation implications depend on full, final data, regulatory feedback, and future company disclosures.